Adam Schayowitz

CIK: 0002127119

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (16.7%)

Position reduction

Option Exercises (M)1 (16.7%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

FTH

Faeth Therapeutics, Inc.

Director

ZYME

Zymeworks Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

FTH
Faeth Therapeutics, Inc.
Oct 23, 2026
Award(A)
Stock Option (right to buy)
Direct
25K shares-
ZYME
Zymeworks Inc.
Oct 9, 2026
Exercise(M)
Direct
37K shares-
ZYME
Zymeworks Inc.
Oct 9, 2026
Sale(S)
Direct
13.8K shares at avg. $25.85$358K
ZYME
Zymeworks Inc.
Apr 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-
ZYME
Zymeworks Inc.
Apr 9, 2026
Award(A)
Restricted Stock Unit
Direct
47K shares-
ZYME
Zymeworks Inc.
Apr 9, 2026
Award(A)
Performance Stock Unit
Direct
76K shares-

		Type	Shares	Price		Ownership
Oct 23, 2026	FTH Faeth Therapeutics, Inc.	Award(A) Stock Option (right to buy)	25,000	-	-	Direct
Oct 9, 2026	ZYME Zymeworks Inc.	Exercise(M)	37,037	-	$0	Direct
Oct 9, 2026	ZYME Zymeworks Inc.	Sale(S)	13,832	$25.85	$357,557	Direct
Apr 9, 2026	ZYME Zymeworks Inc.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct
Apr 9, 2026	ZYME Zymeworks Inc.	Award(A) Restricted Stock Unit	47,000	-	-	Direct
Apr 9, 2026	ZYME Zymeworks Inc.	Award(A) Performance Stock Unit	76,000	-	-	Direct

1-6 of 6 transactions

About Schayowitz Adam

Schayowitz Adam (SEC CIK 0002127119) files insider reports with the SEC as Director of Faeth Therapeutics, Inc. (FTH) and EVP, Head of R&D of Zymeworks Inc. (ZYME).

Signal8 holds 5 ownership filings by Schayowitz Adam (2 Form 3, 3 Form 4), filed between Apr 10, 2026 and Oct 27, 2026. Those filings report 6 transactions, from Apr 9, 2026 to Oct 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schayowitz Adam's filings is in MIDDLETOWN, DE.

Recent filings by Schayowitz Adam

Oct 23, 2026: Grant or award of FTH derivative securities (Form 4, code A).
Oct 9, 2026: Option exercise of ZYME shares (Form 4, code M).
Oct 9, 2026: Open-market sale of ZYME shares (Form 4, code S).
Apr 9, 2026: Grants or awards of ZYME derivative securities (3 lines, Form 4, code A).

Other insiders filing for Faeth Therapeutics, Inc. (FTH)

Vousden Karen H, Director
Khosla Ventures VI, L.P., 10% Owner
Craver Josiah, PAO
Parikh Anand Kiran, President and CEO
STEPHENSON BRIAN C, Chief Financial Officer
Ramasastry Saira, Director

How to read Form 4 transaction codes